‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

BACKGROUND: The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension. METHODS: Atta...

Descripción completa

Detalles Bibliográficos
Autores principales: Vissing, John, Jacob, Saiju, Fujita, Kenji P., O’Brien, Fanny, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320935/
https://www.ncbi.nlm.nih.gov/pubmed/32189108
http://dx.doi.org/10.1007/s00415-020-09770-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320935/
https://www.ncbi.nlm.nih.gov/pubmed/32189108
http://dx.doi.org/10.1007/s00415-020-09770-y

Ejemplares similares